Trends of Platinum and Metal-Arene Anticancer Drugs Based on Natural Products

被引：0

作者：

Ge Chao ^{[1
]}

Lu Meng-Di ^{[1
]}

Zhang Zi-You ^{[1
]}

Chen Jun ^{[1
]}

Wang Meng-Meng ^{[1
]}

Xue Xu-Ling ^{[1
]}

Qian Yong ^{[1
]}

Liu Hong-Ke ^{[1
]}

机构：

[1] Nanjing Normal Univ, Sch Chem & Mat Sci, Nanjing 210023, Peoples R China

来源：

CHINESE JOURNAL OF INORGANIC CHEMISTRY | 2020年 / 36卷 / 04期

关键词：

platinum; arene-metal complexes; natural products; anticancer drugs; INSECT ANTIFEEDANT ACTIVITY; IN-VITRO; RUTHENIUM(II)-ARENE COMPLEXES; BIOLOGICAL EVALUATION; GLYCYRRHETINIC ACID; RUTHENIUM COMPLEXES; ANTITUMOR-ACTIVITY; CRYSTAL-STRUCTURE; CURCUMIN; APOPTOSIS;

D O I：

10.11862/CJIC.2020.086

中图分类号：

O61 [无机化学];

学科分类号：

070301 ; 081704 ;

摘要：

More than 50% of modern drugs used clinically come from natural products, which cart prevent tumor growth and progression by influencing multiple biological pathways such as blocking cell cycle progression, inhibiting cancer cell survival signaling pathway and regulating immune cells. They also show low toxicity to normal tissues. Metal antitumor drugs represented by cisplatin have been widely-used in clinical practice. However, they also have severe drug resistance and side effects, such as nephrotoxicity and neurotoxicity. Therefore, modified platinum drugs with natural products are beneficial for overcoming their deficiencies. On the other hand, the emergence of arene-metal complexes provides more possibilities for the development of high-efficiency and low-toxicity anticancer drugs due to their good water solubility and low toxicity towards normal organisms. Combining the respective advantages of natural products and metals opened up new opportunities for the development of anti-cancer drugs, and the development of metal complexes based on natural products as anticancer agents has become a research hotspot. In this paper, the research and mechanism of platinum and. arene-metal complexes based on natural products are reviewed comprehensively, and the future development in this field has prospected.

引用

页码：597 / 606

页数：10

共 107 条

[1] Ruthenium Complexes: An Emerging Ground to the Development of Metallopharmaceuticals for Cancer Therapy [J].

Abid, Mohammad ;

Shamsi, Farheen ;

Azam, Amir .

MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2016, 16 (10) :772-786

[2] An in vitro study of amygdalin alone and complexed with Se(IV), Au(III), Ru(III), and V(III) ions: Structure, morphology, and pharmacology [J].

Adam, Abdel Majid A. .

JOURNAL OF MOLECULAR STRUCTURE, 2019, 1195 :43-57

[3]

Aggarwal BB, 2003, ANTICANCER RES, V23, P363

[4] In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer [J].

Aird, RE ;

Cummings, J ;

Ritchie, AA ;

Muir, M ;

Morris, RE ;

Chen, H ;

Sadler, PJ ;

Jodrell, DI .

BRITISH JOURNAL OF CANCER, 2002, 86 (10) :1652-1657

[5] Ruthenium antimetastatic agents [J].

Alessio, E ;

Mestroni, G ;

Bergamo, A ;

Sava, G .

CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2004, 4 (15) :1525-1535

[6]

Alessio E, 2004, MET IONS BIOL SYST, V42, P323

[7]

Alessio E, 2015, INVEST NEW DRUGS, V33, P201

[8]

Alessio E, 2018, METAL IONS LIFE SCI, V18, P141, DOI 10.1515/9783110470734-005

[9] Bioavailability of curcumin: Problems and promises [J].

Anand, Preetha ;

Kunnumakkara, Ajaikumar B. ;

Newman, Robert A. ;

Aggarwal, Bharat B. .

MOLECULAR PHARMACEUTICS, 2007, 4 (06) :807-818

[10] Ruthenium-based chemotherapeutics: are they ready for prime time? [J].

Antonarakis, Emmanuel S. ;

Emadi, Ashkan .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (01) :1-9

← 1 2 3 4 5 6 7 8 9 10 →